Lexaria Bioscience
LEXX • NASDAQ
Lexaria Bioscience is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Richard C. Christopher, with a market cap of $16.5M.
CEORichard C. Christopher
Market Cap$16.5M
Biotechnology
Healthcare
Employees3.0
Websitelexariabioscience.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Lexaria Bioscience
Date
Monday, April 13, 2026 (in 2 months)
Timing
Time TBD (2:00 PM New York)
Fiscal Period
Q2 2026
EPS Estimate
-$0.11
Revenue Estimate
$100.0K
Earnings History
Past 11 earnings reports for Lexaria Bioscience
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2025 | Q3 2025 | -$0.21Est: -$0.15 | -40.0% | $174.0KEst: $138.2K | +25.9% |  10-Q |
| Apr 14, 2025 | Q2 2025 | -$0.15 | — | $174.0KEst: $100.0K | +74.0% | 10-Q |
| Jan 10, 2025 | Q1 2025 | -$0.16Est: -$0.12 | -33.3% | $183.9KEst: $100.0K | +83.9% | 10-Q |
| Nov 26, 2024 | Q4 2024 | -$0.15Est: -$0.11 | -36.4% | $84.0KEst: $150.0K | -44.0% | 10-K |
| Jul 12, 2024 | Q3 2024 | -$0.13Est: -$0.10 | -30.0% | $84.0KEst: $150.0K | -44.0% | 10-Q |
| Apr 9, 2024 | Q2 2024 | -$0.06Est: -$0.10 | +40.0% | $145.0K | — | 10-Q |
| Jan 12, 2024 | Q1 2024 | -$0.13 | — | $151.3K | — | 10-Q |
| Nov 20, 2023 | Q4 2023 | -$0.12Est: -$0.13 | +7.7% | -Est: $170.0K | -100.0% | — |
| Jul 14, 2023 | Q3 2023 | -$0.37 | — | $93.2K | — | 10-Q |
| Apr 14, 2023 | Q2 2023 | -$0.22 | — | $35.0K | — | — |
| Jan 17, 2023 | Q1 2023 | -$0.30 | — | $101.5K | — | — |